Amphivena Therapeutics, Inc. — Cyborg Score 5/10

Mixed
Immuno-oncology T-cell engager therapeutics

Strategic Profile

The company's lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy, and in parallel, drives improved T cell effector function. The company is advancing AMV564 through Phase 1 clinical development across multiple solid tumor indications and hematologic malignancies.

Cyborg Score Rationale

Amphivena demonstrates a validated technology platform with clinical proof-of-concept (Phase 1 data showing complete response), significant institutional backing ($88.5M raised), and a strategic focus on immuno-oncology—a high-value market segment. However, the company remains pre-clinical to early clinical stage with limited recent public data (last major update June 2021), modest headcount (17 employees as of 2026), and no evidence of partnership or accelerated development milestones.

Top Insights

  • Founded in 2012, Amphivena emerged from Affimed spinco structure, signaling technology licensing or spin-off origins
  • Phase 1 data support dose and schedule of AMV564 for expansion cohorts in selected solid tumor indications, indicating advancement readiness as of June 2021
  • The company has 17 total employees (as of 2026), suggesting limited infrastructure and potential outsourced clinical/manufacturing operations
  • Amphivena Therapeutics raised a total of $88.5M, with Series C funding completed in September 2019

Named Competitors

  • BiTE Platform — Established bispecific T-cell engager platform for hematologic malignancies
  • CAR-T Therapies — Chimeric antigen receptor T-cell therapies for blood cancers
  • Checkpoint Inhibitors — Anti-PD-1 and anti-PD-L1 immunotherapies (e.g., Keytruda)
  • Bispecific T-cell Engagers — Early-stage bispecific platform addressing tumor immunosuppression

Recent Developments

  • (June 2021) Presented comprehensive Phase 1 monotherapy and first combination therapy clinical data at ASCO Annual Meeting for AMV564 in solid tumor patients
  • (December 2020) Announced first patient dosed in Phase 1 dose expansion study of AMV564
  • (September 2019) Closed $62 million Series C financing round co-led by NanoDimension and Qiming Venture Partners

Open the full interactive Amphivena Therapeutics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →